Plain-English translation of NCT07100080 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called Izalontamab Brengitecan to see if it works better than standard chemotherapy for people with a specific type of lung cancer that has stopped responding to their first-line treatment. You would be randomly assigned to receive either the new medication or the standard chemotherapy combination that doctors typically use. The goal is to find out which treatment helps patients live longer and feel better.
People with this type of lung cancer often see their initial treatment stop working after a while, and doctors need better options. This medication is designed to attack cancer cells in a new way, and researchers want to know if it can help patients who have reached this point in their treatment journey.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly for check-ups, blood tests, and imaging scans to monitor how the treatment is working. You would either take the new medication or receive standard chemotherapy infusions, depending on which group you are randomly assigned to. The study involves about 500 participants total, and you would be followed for as long as the treatment is helping your cancer and you wish to continue.
AI-generated summary from trial data · Aug 31, 2026 · Not medical advice
United States